Valores pretratamiento e inducidos por el tratamiento de enolasa específica de neurona en pacientes con cáncer de pulmón microcítico: estudio prospectivo, abierto

Erbaycu, Ahmet Emin; Gunduz, Ayriz; Batum, Ozgur; Ucar, Zeynep Zeren; Tuksavul, Fevziye; Guclu, Salih Zeki.
Arch. bronconeumol. (Ed. impr.) ; 46(7): 364-369, jul. 2010. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-83319

Documentos relacionados

  1. A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma.
  2. Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review.
  3. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
  4. Chemotherapy versus best supportive care for extensive small cell lung cancer.
  5. Albumin-to-D-dimer ratios: A novel prognostic factor for evaluating first-line chemotherapy efficacy in advanced lung adenocarcinoma patients.
  6. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
  7. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
  8. Outcomes of extensive stage extrapulmonary small cell cancer.
  9. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.
  10. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.